about
Cancer immunotherapy: the beginning of the end of cancer?Modulation of GITR for cancer immunotherapyPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsT cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccinationAntibody Therapies in Cancer.Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapiesThe availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interactionOX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.Three steps to breaking immune tolerance to lymphoma: a microparticle approach.TNF superfamily protein-protein interactions: feasibility of small- molecule modulationEffector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotypeTumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapySA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccinesOX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancerIdentification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.CD40 ligation reverses T cell tolerance in acute myeloid leukemia.Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need.Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood.Ipilimumab in prostate cancer.The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Targeting tumor-necrosis factor receptor pathways for tumor immunotherapyOvercoming tumor-mediated immunosuppression.OX40, OX40L and Autoimmunity: a Comprehensive Review.New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
P2860
Q26752277-DADDC6CD-4B7D-4F84-8D76-3C66C5FBE276Q26853557-BF709AE8-0528-4D85-B40E-42C34CE570C4Q28075712-8857D46F-CE76-49E2-B25F-D40768F63EF9Q28274469-899A4E64-06AC-4264-BAAC-572CE64F6F8FQ31104000-920B9279-03DA-4953-9B06-8420D844C93FQ33610214-F5CA004D-1D35-4191-A881-CDF717858352Q33617937-43B110F6-2D0F-4303-B9CE-8647B89989C9Q34397451-2CDAE0B9-5367-4357-8BB9-94A48107A2F3Q34511672-9CF2CAC4-3644-4582-AA3C-EAC7C9366306Q34778826-C384987F-4DCB-4071-B0A4-D5EE3A3E83E0Q34954124-C6B7F8DD-3245-4DBC-8D03-5D7AA92A21E6Q35118177-B6154373-3721-4D42-811B-DCC0BEE7E6FEQ35328686-24E3EA2E-05AA-4520-834B-70C717F3E217Q35534271-93D2C9C2-F96B-4E7B-9225-780FFAA79110Q35922726-9F1A4D4E-0CFC-41A5-B56D-45EB5D61531BQ36198732-1792E76D-E8F0-448D-BDC8-7EABEA31D4D1Q36340873-049F8ABA-B439-4636-B068-965D58653488Q36349514-CFA473C1-24F7-4115-A027-EFA01ED2521AQ36487245-7987B0C2-D90B-4839-9D6F-5D3A80E14443Q36545813-BC6F2FD1-D2CC-4A4F-913C-142E6655A9F3Q36603032-A2FC94D6-D907-49F2-90DE-4EB2A075DDB9Q36653524-D170CFEA-056D-4A0C-991A-292D1A3C5E92Q36793408-024AE63F-B572-416C-9BEF-CC010C9A84E8Q36907372-090D6B6D-1608-4861-ACFD-1FC5354CC3A4Q37086513-F708DDCD-7A2D-4CEA-B4F4-D6203274FC87Q37125732-A930D02D-7B39-400D-84A1-C1D4E6271EFCQ38069640-21EC8B4B-C7F4-4897-BC94-A4A2CA8F5FAAQ38081999-E242D18F-BB96-4D0A-89B8-B7F80B028424Q38088635-E8EB2DE3-462A-4F31-A38A-0888933E0F55Q38108836-6146E033-120A-4A30-8E28-1B4B5C55BA79Q38120535-DA40467F-7D03-44B2-9433-FF4ADCC51F4CQ38214095-C71767A7-F469-4906-A680-E565486C1D43Q38262255-C976BC81-55B7-4DB9-A0B9-FF9CCD2B73FCQ38555213-00BDE085-D595-4CF2-AB99-54C7074173A8Q38673585-A547AAB7-A90B-45BE-AE43-58595FB213F1Q38684474-2A81F9EB-7F53-4AB1-9426-62A9426A4A06Q38739860-FB2DB350-6518-4110-A6BE-0AAA8453AB83Q38770814-BDB96134-4F92-452A-8D98-DF89F91C108AQ38779877-65F1C833-26C6-4A4B-BE7D-62C8E07A9796Q38878906-9C2ED6A1-F493-4423-8007-D28F27270F1E
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Science gone translational: the OX40 agonist story
@ast
Science gone translational: the OX40 agonist story
@en
Science gone translational: the OX40 agonist story
@nl
type
label
Science gone translational: the OX40 agonist story
@ast
Science gone translational: the OX40 agonist story
@en
Science gone translational: the OX40 agonist story
@nl
prefLabel
Science gone translational: the OX40 agonist story
@ast
Science gone translational: the OX40 agonist story
@en
Science gone translational: the OX40 agonist story
@nl
P2093
P2860
P3181
P1476
Science gone translational: the OX40 agonist story
@en
P2093
Andrew D. Weinberg
Brendan D. Curti
Magdalena Kovacsovics-Bankowski
Nicholas P. Morris
Walter J. Urba
P2860
P304
P3181
P356
10.1111/J.1600-065X.2011.01069.X
P407
P577
2011-11-01T00:00:00Z